MAYO CLINIC LABORATORIES

# Test Definition: FOXOF

Alveolar Rhabdomyosarcoma (ARMS), 13q14 (FOXO1 or FKHR) Rearrangement, FISH, Tissue

## Overview

### Useful For

Detection of *FOXO1* rearrangements irrespective of the *FOXO1* fusion partner gene

Supporting the diagnosis of alveolar rhabdomyosarcomas when used in conjunction with an anatomic pathology consultation

### Reflex Tests

| Test Id | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| _PBCT | Probe, +2 | No, (Bill Only) | No |
| _PADD | Probe, +1 | No, (Bill Only) | No |
| _PB02 | Probe, +2 | No, (Bill Only) | No |
| _PB03 | Probe, +3 | No, (Bill Only) | No |
| _IL25 | Interphases, <25 | No, (Bill Only) | No |
| _I099 | Interphases, 25-99 | No, (Bill Only) | No |
| _I300 | Interphases, >=100 | No, (Bill Only) | No |

### Testing Algorithm

This test includes a charge for the probe application, analysis, and professional interpretation of results for one probe set (2 individual fluorescence in situ hybridization probes). No analysis charges will be incurred if an insufficient number of representative cells are available for analysis.

Appropriate ancillary probes may be performed at consultant discretion to render comprehensive assessment. Any additional probes will have the results included within the final report and will be performed at an additional charge.

### Method Name

Fluorescence In Situ Hybridization (FISH)

### NY State Available

Yes

## Specimen

### Specimen Type

Tissue

### Ordering Guidance

This test does not include a pathology consultation. If a pathology consultation is requested, order PATHC / Pathology Consultation, and appropriate testing will be added at the discretion of the pathologist and performed at an additional charge.

Multiple oncology (cancer) gene panels are also available. For more information see Hematology, Oncology, and Hereditary Test Selection Guide.

## Shipping Instructions

Advise Express Mail or equivalent if not on courier service.

## Necessary Information

**1. A pathology report is required for testing to be performed**. If not provided, appropriate testing and/or interpretation may be compromised or delayed. Acceptable pathology reports include working drafts, preliminary pathology, or surgical pathology reports.

**2. The following information must be included in the report provided.**

-Patient name

-Block number - **must be on all blocks, slides, and paperwork**

-Date of collection

-Tissue source

**3. A reason for testing must be provided.** If this information is not provided, an appropriate indication for testing may be entered by Mayo Clinic Laboratories.

## Specimen Required

**Submit only 1 of the following specimens:**

**Preferred:**

**Specimen Type:** Tissue block (fresh tissue is **not acceptable**)

**Collection Instructions:**

1. Submit a formalin-fixed, paraffin-embedded tumor tissue block.
2. Blocks prepared with alternative fixation methods (eg, Prefer, Bouin's) will be attempted but are less favorable for successful results. Provide fixation method used.

**Additional Information:**

1. Paraffin-embedded specimens can be from any anatomic location (skin, soft tissue, lymph node, etc).
2. Decalcified paraffin-embedded specimens will have testing attempted; however, the success rate is approximately 50%. **Testing may be canceled** if sufficient tumor tissue is not present.
3. **Submitted fresh tissue specimens will be canceled upon receipt**. If only fresh tissue is available, embed in paraffin prior to sending.

**Acceptable:**

**Specimen Type:** Tissue slides

**Slides**: 1 Hematoxylin and eosin-stained and 4 unstained

**Collection Instructions**: Submit 1 slide stained with hematoxylin and eosin and 4 consecutive unstained, positively charged, unbaked slides with 5 micron-thick sections of the tumor tissue.

**Additional Information:** Broken or cracked unstained slides will be rejected. Stained slides that were broken and repaired (ie, double mounted) at the client site will not be rejected, as, in most cases, they can still be reviewed under

the microscope. However, due to the double mounting, digital scanning cannot be performed.

### Forms
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.

### Specimen Minimum Volume
Slides: 1 Hematoxylin and eosin stained and 2 unstained

### Reject Due To

| | |
|---|---|
| Broken or cracked unstained slides | Reject |
| Broken or cracked stained slides that cannot be repaired | Reject |

### Specimen Stability Information

| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Tissue | Ambient (preferred) | | |
| | Refrigerated | | |

## Clinical & Interpretive

### Clinical Information
Rhabdomyosarcomas are a heterogeneous group of malignant tumors showing skeletal muscle differentiation. They can be divided into 3 subtypes: alveolar, embryonal, and pleomorphic. The rarer alveolar rhabdomyosarcomas (ARMS) are seen in older children, are more likely to occur in limbs, and are associated with higher stage disease and an unfavorable prognosis.

Most cases of ARMS are associated with the rearrangement of the *FOXO1* gene on chromosome 13. Detection of a *FOXO1* rearrangement by fluorescence in situ hybridization may help to support a histologic diagnosis of ARMS.

### Reference Values
An interpretive report will be provided.

### Interpretation
*FOXO1* will be clinically interpreted as positive, negative, or equivocal.

A neoplastic clone is detected when the percent of cells with an abnormality exceeds the normal cutoff for the FOXO1 fluorescence in situ hybridization probe set.

A positive result is consistent with rearrangement of the *FOXO1* gene and likely reflects *FOXO1* fusion with a partner gene. The significance of this finding is dependent on the clinical and pathologic features.

A positive result is consistent with the presence of an *FOXO1* rearrangement and likely reflects *FOXO1* fusion with a partner gene.

A positive result is consistent with a subset of alveolar rhabdomyosarcomas (ARMS). The significance of this finding is dependent on the clinical and pathologic features.

A negative result suggests a *FOXO1* gene rearrangement is not present but does not exclude the diagnosis of ARMS.

## Cautions

This test is not approved by the US Food and Drug Administration, and it is best used as an adjunct to existing clinical and pathologic information.

This fluorescence in situ hybridization (FISH) assay does not rule out other chromosome abnormalities.

Fixatives other than formalin (eg, Prefer, Bouin's) may not be successful for FISH assays. Non-formalin fixed specimens will not be rejected.

Paraffin-embedded tissues that have been decalcified may not be successful for FISH analysis. The success rate of FISH studies on decalcified tissue is approximately 50%, but FISH will be attempted if sufficient tumor is present for analysis.

Fluorescence in situ hybridization studies will be attempted if sufficient tumor is present for analysis. The pathologist reviewing the hematoxylin and eosin-stained slide may find it necessary to cancel testing if insufficient tissue/tumor is available for testing.

If no FISH signals or a lack of sufficient tumor tissue are observed post-hybridization, the case will be released indicating a lack of FISH results.

Broken or cracked unstained slides are not compatible with the instrumentation used in our performing laboratories and will be rejected. Additional material may be requested.

Attempts will be made to repair broken or cracked stained slides; however, if they are unable to be repaired (ie, shattered in transit), they will be rejected and discarded due to safety concerns.

## Clinical Reference

1. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to *PAX3* in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;5(3):230-235
2. Nishio J, Althof PA, Bailey JM, et al. Use of a novel FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of alveolar rhabdomyosarcoma. Lab Invest. 2006;86(6):547-556

3. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 2001;20(40):5736-5746
4. WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. 5th ed. IARC; 2020. WHO Classification of Tumours Series. Vol. 3, 203-208

## Performance

### Method Description
The test is performed using a commercially available FOXO1 dual-color, break-apart strategy fluorescence in situ hybridization probe set. Formalin-fixed, paraffin-embedded tissues are cut at 5 microns and mounted on positively charged glass slides. The selection of tissue and the identification of target areas on the hematoxylin and eosin (H and E)-stained slide are performed by a pathologist. Using the H and E-stained slide as a reference, target areas are etched with a diamond-tipped engraving tool on the back of the unstained slide to be assayed. The probe set is hybridized to the appropriate target areas, and 2 technologists independently analyze 50 interphase nuclei (100 total) with the results expressed as the percent of abnormal nuclei.(Unpublished Mayo method)

### PDF Report
No

### Day(s) Performed
Monday through Friday

### Report Available
7 to 10 days

### Specimen Retention Time
Slides and hematoxylin and eosin used for analysis are retained by the laboratory in accordance with regulatory requirements. Client provided paraffin blocks and extra unstained slides (if provided) will be returned after testing is complete.

### Performing Laboratory Location
Mayo Clinic Laboratories - Rochester Main Campus

## Fees & Codes

### Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.

### Test Classification

# Test Definition: FOXOF

Alveolar Rhabdomyosarcoma (ARMS), 13q14 (FOXO1 or FKHR) Rearrangement, FISH, Tissue

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

## CPT Code Information

88271 x 2, 88291-DNA probe, each (first probe set), Interpretation and report
88271 x 2-DNA probe, each; each additional probe set (if appropriate)
88271-DNA probe, each; coverage for sets containing 3 probes (if appropriate)
88271 x 2-DNA probe, each; coverage for sets containing 4 probes (if appropriate)
88271 x 3-DNA probe, each; coverage for sets containing 5 probes (if appropriate)
88274 w/modifier 52-Interphase in situ hybridization, <25 cells, each probe set (if appropriate)
88274-Interphase in situ hybridization, 25 to 99 cells, each probe set (if appropriate)
88275-Interphase in situ hybridization, 100 to 300 cells, each probe set (if appropriate)

## LOINC® Information

| Test ID | Test Order Name | Order LOINC® Value |
|---|---|---|
| FOXOF | FOXO1 (13q14), ARMS, FISH, Ts | 93807-6 |

| Result ID | Test Result Name | Result LOINC® Value |
|---|---|---|
| 52211 | Result Summary | 50397-9 |
| 52213 | Interpretation | 69965-2 |
| 52389 | Result | 62356-1 |
| CG752 | Reason for Referral | 42349-1 |
| 52214 | Specimen | 31208-2 |
| 52215 | Source | 31208-2 |
| 52216 | Tissue ID | 80398-1 |
| 52217 | Method | 85069-3 |
| 54592 | Additional Information | 48767-8 |
| 52218 | Released By | 18771-6 |
| 52824 | Disclaimer | 62364-5 |